China
Three sources explain why a notification by Nanjing’s IP centre in China banning AI use in patent drafting is too broad and could be difficult to enforce
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
The deal could mean that hundreds of licensees in the pool would have access to a broader range of VVC patents
Sponsored
Sponsored
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Yifan Lu of Tahota Law Firm explore Beijing's pioneering role among eight Chinese provinces and municipalities designated to work on the development of the country’s data intellectual property rights framework -
Sponsored by Tahota Law FirmCharles Feng and Lian Xue of Tahota Law Firm analyse judicial interpretations of China’s Trademark Law and explain why the date of infringement should be the starting point for the ‘preceding three years’ non-use period
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaoping of Wanhuida Intellectual Property says the methodology often applied in assessing inventiveness in pharmaceutical patent litigation cases is set to be used in re-examination and invalidation proceedings after the CNIPA makes an invalidation decision a quasi-precedent
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm begins a two-part guide to intellectual property protection in China by considering the general provisions, before focusing on the key issues and legal framework concerning trademarks
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm concludes a two-part series on intellectual property protection in China by looking at copyright, unfair competition, and a change to the appeals procedure for technology-related disputes
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
